KeWei Gong

Hubei University of Medicine — China

Medicine · Health Sciences

16h-index1.7kcitations195works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(95), HER2/EGFR in Cancer Research(70), Radiopharmaceutical Chemistry and Applications(28), Glycosylation and Glycoproteins Research(26), Cancer Research and Treatments(25)

Publications195 total

Functional characterization of a novel JPH2 variant (p.R160H) associated with dilated cardiomyopathy
BMC Cardiovascular Disorders·2025Open Access
Causal effect of education on low back pain, intervertebral disc degeneration and sciatica: Mendelian randomization study
Future Science OA·2025Open Access
Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Methods 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Charge-dependent spectral softenings of primary cosmic-rays from proton to iron below the knee
arXiv (Cornell University)·2025Open Access
Testing the Incremental Contribution of Maladaptive Metacognition to Suicidal Ideation and Suicide Attempts
Clinical Psychology & Psychotherapy·2025Open Access
Diminished reactivity effect of confidence rating on perceptual decision-making in depression
Frontiers in Neuroscience·2025Open Access
Study on pathogen monitoring and critical patient treatment strategies for acute community-acquired lower respiratory tract infections
Pakistan Journal of Medical Sciences·2025Open Access
Position reconstruction for HERD Plastic Scintillator Detector using KAN neural network
Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment·2025· 1 cited
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessation
2025Open Access
Cross-calibration of the energy response of the gamma-ray detectors on board GECAM-B
Astronomy and Astrophysics·2025· 1 citedOpen Access
Microenvironment-activatable nanoagent for real-time NIR-II monitoring and targeted therapy of arterial restenosis
Biomaterials·2025· 2 cited
page 1 of 10Next →

Frequent Co-authors

Neil A. O’Brien(10), Dennis J. Slamon(10), Martina S.J. McDermott(9), Benjamin Hoffstrom(9), Ming Lu(9), Kevin Chau(9), John A. Glaspy(9), Tong Luo(8), Min Liang(8), Leonard Presta(8), Jun Zhang(7), Weiping Jia(6), Aldons J. Lusis(5), Jenny J. Hong(5), Simon Davenport(5), Michael F. Press(5), Abram Handly‐Santana(5), Joan S. Brugge(5), Wei Lei(5), Kezhi Liu(5)